Chugai Pharmaceutical Co., Ltd. Web Site ... 10/27/2008 Data from Overseas Phase III Trial (LITHE) of "Actemra ®," a Humanized Anti-Human IL-6 Receptor ...

humanized monoclonal antibody. Gastric cancer # Phase III Multinational study. Breast cancer (adjuvant) # Phase III Multinational study. Non-small cell lung cancer

The Chugai Humanized Anti-Human Recombinant Interleukin-6 Monoclonal Antibody (CHARISMA) study evaluated the safety and efficacy of repeated infusions of tocilizumab alone and in ...

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced today that the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody, Actemra(R) [ generic ...

Chugai Pharma USA LLC is a research-based, global pharmaceutical company that discovers ... MRA (tocilizumab) is a humanized monoclonal antibody against the human ...

Free Online Library: Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid ...

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced today that the humanized anti-human IL-6 receptor monoclonal antibody, Actemra, co-developed by Chugai and ...

... Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in Europe   (Chugai)   03-Dec-2007 "Actemra®," a Humanized Anti-Human IL ...

Chugai also is developing Actemra (tocilizumab), a new humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody whose novel mechanism of action provides a new and ...

Chugai Pharma USA ... Humanized antibody against the IL-6 receptor. In Phase I studies in the US and Phase II in ...

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

humanized antibody Molecular medicine A recombinant DNA product which ? non-human ... Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy ... by JCN Newswires

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on Rheumatoid Arthritis Patients

tocilizumab: Actemra: AI: monoclonal antibody: humanised anti-IL-6 receptor monoclonal antibody: sJIA: 3 : 2010: Chugai: R1594 ocrelizumab: NME: monoclonal antibody: humanized anti-CD20 monoclonal ...

Roche and Chugai to jointly develop and promote Chugai?s promising new Rheumatoid ... MRA is a humanized anti-human IL-6 receptor monoclonal antibody and with its novel ...

Find out key developments for CHUGAI PHARMACEUTICAL CO LTD 4519.T at Reuters.com ... Ltd., which is owned by Roche, regarding the manufacturing of "Actemra", a Humanized Anti ...

Chugai Pharmaceutical Discloses Clinical Trial ... III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on... Chugai ...

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma ...

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. announced today that the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody, Actemra(R) [ generic ...

Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by ... University of Tokushima, Tokushima, and Fuji-Gotemba Research Laboratory, Chugai ...

Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy ... by JCN Newswires ... A Humanized Antibody Against CD40 (SGN-40) is Well Tolerated and Active in Non-Hodgkin's ...

Here, Maini et al (Arthritis Rheum 2006; 54: 2817) report the results of the CHARISMA (Chugai Humanized Anti-Human Recombinant Interleukin-Six Monoclonal Antibody) Study, the ...

Tokyo - Chugai Pharmaceutical Co., Ltd [Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereinafter, Chugai)] announced that the humanized anti-human IL-6 (interleukin-6 ...

Read news articles related to Chugai ... Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal ...

Read news articles related to Chugai to ... Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal ...

MRA (Humanized anti-IL-6 receptor Mab) Chugai (Phase II for R.A.) CD4 antibody. TolerRxInc. CD18 antibody (LDP-01)

Get Chugai Pharmaceutical Co. Ltd. (4519) stock research & investing information. ... Avastin, a humanized anti- vascular endothelial growth factor monoclonal antibody;

In a multicentre, randomized clinical trial in patients with established RA using multiple doses of tocilizumab ? the CHARISMA study (Chugai Humanized Anti-human Recombinant ...

Get Chugai Pharmaceutical Co. Ltd. (4519.T) stock research & investing information. ... Avastin, a humanized anti- vascular endothelial growth factor monoclonal antibody;